First sale of antimicrobial face masks in Canada
(EKO-TSX Venture Exchange)
MONTREAL, Aug. 30 /CNW Telbec/ - NOVEKO INTERNATIONAL INC. ("Noveko" or
"the Company") announces that, through its subsidiary Noveko Inc., it has
closed an important sale of antimicrobial face masks to Medi-Select
(http://www.medi-select.ca), a leader in the distribution of medical equipment
and supplies. This first order of several million face masks represents sales
of $2.3 million and immediately follows Health Canada's issuance of an
establishment licence to Noveko Inc., as announced on August 28, 2007.
These face masks are derivative products from Noveko's patented
antimicrobial technology and provide 100% bioprotection (superior to
N-99-approved products), while facilitating breathing and offering more
comfortable skin contact than any other face mask currently on the market.
"We are proud to have closed our first important sale of antimicrobial
face masks to Medi-Select, which serves an extensive client base in the health
care field as well as medical equipment and supply purchasing pools, primarily
in Quebec, but also in Ontario and the Atlantic Provinces. Our different face
mask models will perfectly fulfill the needs of its clientele of hospitals,
medical, dental and surgical clinics, extended-care facilities and the general
public, notably to help prevent pandemics," indicated Alain Bolduc, President
and Chief Operating Officer of Noveko.
Philippe Cantin, President of Medi-Select, said he was very pleased
"about this agreement with Noveko which attests to our concern for providing
our clients with innovative high-performance products. The timing of Noveko's
antimicrobial face masks is perfect and allows us to offer our clients
specializing in health care a higher protection means that is unique on the
The establishment licence that Noveko Inc. was recently granted by Health
Canada kickstarted the marketing of the Company's antimicrobial face masks in
Canada. So far, Noveko's antimicrobial technology has been delivered a U.S.
patent by the United States Patent and Trademark Office (May 2006) and a
Eurasian patent by the Eurasian Patent Office, located in Moscow (July 2007).
The Company has other similar international patents pending.
Profile of Noveko International Inc.
Noveko International Inc. currently has four subsidiaries: S.A.S. ECM,
Noveko Inc., Laboratoire SyMa Inc. ("SyMa") and Bolduc Leroux Inc. (BLI). ECM
specializes in the design and marketing of portable real-time ultrasound
scanners for use in veterinary and human medicine. Noveko Inc. develops the
Company's biomedical and environmental business, specifically its patented
antimicrobial filtration technology and derivative products (antimicrobial
face masks and air filters). SyMa specializes in the manufacture of
sanitizers, more specifically the antimicrobial products (for hands, feet and
surfaces) sold under the Azuro trademark. For its part, BLI specializes in the
custom processing and distribution of steel products based on client
specifications and designs. It has also developed and markets a line of
downdraft particle extraction tables for various industrial, commercial and
pharmaceutical markets. Operating since September 2002, the Company was listed
on the TSX Venture Exchange on February 3, 2004.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, (514)
344-3030, http://www.noveko.com; Marie-Claude Leroux, Morin Public Relations,
(514) 289-8688, ext. 224, Cell: (514) 705-5897, email@example.com